BioCentury
ARTICLE | Company News

Applied Molecular Transport, Janssen strike IBD deal

January 29, 2015 1:39 AM UTC

Applied Molecular Transport LLC (South San Francisco, Calif.) granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exclusive worldwide rights to an undisclosed preclinical oral candidate to treat inflammatory bowel disease (IBD). AMT also joined Janssen's JLABS incubator in South San Francisco.

AMT founder and CBO Tahir Mahmood said the companies are not disclosing specific financial terms. AMT is eligible for upfront fees, research support and milestones, plus royalties. ...